Cover Image
市場調查報告書

MediPoint:非血管支架的全球市場分析、預測

MediPoint: Non-Vascular Stents - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 333929
出版日期 內容資訊 英文 288 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:非血管支架的全球市場分析、預測 MediPoint: Non-Vascular Stents - Global Analysis and Market Forecasts
出版日期: 2015年04月01日 內容資訊: 英文 288 Pages
簡介

本報告提供全球非血管支架的市場相關調查、非血管支架的分類、支架置入的有效性、全球主要地區的支架置入束趨勢、市場進入環境、未滿足需求、市場促進因素、阻礙要素及市場機會分析、主要產品比較分析、關注的臨床試驗、各支架區隔、地區的手術數量及支架銷售情況與預測,以及主要企業的簡介等彙整。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 概要
  • 支架置入的分類
    • 腸內支架
    • 胰臟、膽管支架
    • 呼吸道支架
    • 輸尿管支架
  • 支架的類型和臨床性有效性
    • 腸內支架
    • 胰臟、膽管支架
    • 呼吸道支架
    • 輸尿管支架
  • 治療趨勢
    • 美國
    • 歐盟5國
    • 亞太地區
    • 南美
  • 市場進入
    • 產品的引進
    • 法律規章
    • 償付
  • 法律規章上的課題、回收
  • M&A
  • 經濟影響

第4章 未滿足需求

  • 併發症的應對
  • 支架設計上的課題的解除
  • 遞送系統的簡單化
  • 產業及醫生的關係的背離
  • 特定症狀專用的支架
  • 長期、相對臨床資料的不足
  • 開發中產品的重新關注
  • 標準化的不足
  • 降低成本策略
  • 國際註冊表—的需求

第5章 市場機會分析

  • 支架系統的改善
  • 生物分解性支架
  • 藥劑溶出性血管支架
  • 放射線敏化
  • 客制化支架
  • 新興市場

第6章 市場促進因素、阻礙要素

第7章 競爭評估

  • 消化管支架
    • 概要
    • WallFlex (Boston Scientific Corporation)
    • Evolution (Cook Medical)
    • Niti-S (Taewoong Medical)
    • 其他主要已上市消化管支架
  • 膽管支架
    • 概要
    • WallFlex Biliary RX (Boston Scientific Corporation)
    • Cotton-Leung (Amsterdam) (Cook Medical)
    • Bonastent (EndoChoice)
    • 其他已上市膽管支架
  • 呼吸道支架
    • 概要
    • Dumon (Novatech)
    • Aero/Aero DV (Merit Endotek)
    • Ultraflex (Boston Scientific Corporation)
    • 其他主要已上市呼吸道支架
  • 輸尿管支架
    • 概要
    • Polaris Ultra (Boston Scientific Corporation)
    • InLay Optima (C.R. Bard)
    • 其他主要已上市輸尿管支架

第8章 關注的臨床試驗

  • 概要
  • 腸內支架
  • 胰臟、膽管支架
  • 呼吸道支架
  • 輸尿管支架

第9章 現在、未來的企業

  • 企業策略趨勢
  • 企業簡介
    • Allium Medical
    • Boston Scientific Corporation
    • ConMed
    • Cook Medical
    • C.R. Bard
    • Ella-CS
    • Merit Endotek
    • M.I. Tech
    • Micro-Tech (Nanjing)
    • Medtronic (Covidien)
    • Novatech
    • Olympus Corporation
    • Taewoong Medical
    • Xlumena
    • 其他

第10章 市場預測

  • 企業的市場佔有率
    • 美國
    • 歐盟5國
    • 南美
    • 亞太地區
  • 各產品類型市場
    • 全球市場概要
    • 腸內支架
    • 胰臟、膽管支架
    • 呼吸道支架
    • 輸尿管支架
  • 各地區市場
    • 全球市場概要
    • 美國
    • EU
    • 南美
    • 亞太地區

第11章 附錄

圖表

目錄
Product Code: GDME0211MAR

Non-vascular stent technology has evolved over the years such that these devices are routinely used in clinical practice for different indications. Although it is a mature market, both short and long-term complications associated with non-vascular stents continue to persist. This report focuses on four market categories within the non-vascular stent segment, which includes enteral stents (esophageal, gastroduodenal and colonic stents), pancreatic and biliary stents, airways stents and urinary tract stents (ureteral, prostate and urethral stents). The overall non-vascular stent market has been estimated in this report, which covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India (10MM) up to 2021. The report provides an investigation of unmet needs, future adoption trends and compound annual growth rates (CAGR) for each geography and market segment. In addition, this report presents the current market drivers and barriers which will influence the future market growth of non-vascular stents in the 10MM.

Highlights

Key Questions Answered

  • What is the current and future non-vascular stent market outlook in the developed and emerging markets? (Q). What trends are affecting the global non-vascular stents market?
  • Which are the key, high growth markets that stent manufacturers should expand into? (Q). What non-vascular stent segments are growing the fastest?
  • There are a few significant unmet needs. (Q). What are these unmet needs? (Q). What is the scope for more innovation and what are the end-users looking for in their products?
  • Will biodegradable stent systems fulfill these unmet needs? (Q). What is physician perception and market outlook of this technology?
  • What percent of global profits are from emerging markets? (Q). How will this change in the future?
  • Boston Scientific currently dominates the global non-vascular stents market. (Q). What is their market share in the major global economies and which companies constitute the remainder of the market?

Reasons to buy

  • What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading physicians and other stakeholders from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Non-Vascular Stenting Indications
    • 3.2.1. Enteral Stents
    • 3.2.2. Pancreatic and Biliary Stents
    • 3.2.3. Airway Stents
    • 3.2.4. Urinary Tract Stents
  • 3.3. Types of Stents and Clinical Efficacy
    • 3.3.1. Enteral Stents
    • 3.3.2. Pancreatic and Biliary Stents
    • 3.3.3. Airway Stents
    • 3.3.4. Urinary Tract Stents
  • 3.4. Procedure Trends
    • 3.4.1. US
    • 3.4.2. 5EU
    • 3.4.3. Asia-Pacific
    • 3.4.4. South America
  • 3.5. Market Access
    • 3.5.1. Product Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls (2011-2014)
    • 3.6.1. Cordis Corporation Class II Recall of S.M.A.R.T Control Transhepatic Biliary Stent
  • 3.7. Mergers, Acquisitions, and Other Deals
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. Beijing King Health Signs Distribution Agreement With Allium Medical
    • 3.7.3. Cordis Acquires Flexible Stenting Solutions
    • 3.7.4. Allium Medical Enters Into Distribution Agreement With Meizler UCB Biopharma
    • 3.7.5. Gore and ConMed Extend Distribution Agreement
    • 3.7.6. Allium Medical Acquires Gardia Medical
    • 3.7.7. Flexible Stenting Solutions Raises Funds in Series B Financing
  • 3.8. Economic Impact

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Enteral Stents
    • 4.1.2. Pancreatic and Biliary Stents
    • 4.1.3. Airway Stents
    • 4.1.4. Urinary Tract Stents
  • 4.2. Overcoming Stent Design Challenges
    • 4.2.1. Stent Shortening
    • 4.2.2. Stent Fracture
    • 4.2.3. Flexibility
  • 4.3. Simplify Delivery Systems
  • 4.4. Disconnect Between Industry and Physicians
  • 4.5. Indication-Specific Stents
  • 4.6. Lack of Long-Term and Comparative Clinical Data
  • 4.7. Refocus on Pipeline Products
  • 4.8. Lack of Standardization
  • 4.9. Cost-Containment
  • 4.10. Need for An International Procedure Registry

5. Market Opportunity Analysis

  • 5.1. Improve Stent Systems
  • 5.2. Biodegradable Stents
  • 5.3. Drug-Eluting Stents
  • 5.4. Radiosensitization
  • 5.5. Customized Stents
  • 5.6. Emerging Markets

6. Market Drivers and Barriers

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Cancer
    • 6.1.2. Urolithiasis
  • 6.2. Driver: Non-Malignant Stenting Applications to Drive the Market
    • 6.2.1. Drainage
    • 6.2.2. Bariatric Surgery
    • 6.2.3. Neoadjuvant Treatment
    • 6.2.4. Benign Strictures
  • 6.3. Driver: Fully-Covered, Removable Metal Stents To Drive Future Growth
  • 6.4. Driver: Preference for Minimally-Invasive Solutions
  • 6.5. Driver: Increased Life Expectancy
  • 6.6. Driver: Technological Advancements
  • 6.7. Driver: Patient Demand and Awareness
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: Proving Long-Term Efficacy
  • 6.12. Barrier: Medical Device Excise Tax

7. Competitive Assessment

  • 7.1. Gastrointestinal Stents
    • 7.1.1. Overview
    • 7.1.2. WallFlex (Boston Scientific Corporation)
    • 7.1.3. Evolution (Cook Medical)
    • 7.1.4. Niti-S (Taewoong Medical)
    • 7.1.5. Other Key Marketed Gastrointestinal Stents
  • 7.2. Biliary Stents
    • 7.2.1. Overview
    • 7.2.2. WallFlex Biliary RX (Boston Scientific Corporation)
    • 7.2.3. Cotton-Leung (Amsterdam) (Cook Medical)
    • 7.2.4. Bonastent (EndoChoice)
    • 7.2.5. Other Key Marketed Biliary Stents
  • 7.3. Airway Stents
    • 7.3.1. Overview
    • 7.3.2. Dumon (Novatech)
    • 7.3.3. Aero/Aero DV (Merit Endotek)
    • 7.3.4. Ultraflex (Boston Scientific Corporation)
    • 7.3.5. Other Key Marketed Airway Stents
  • 7.4. Urinary Tract Stents
    • 7.4.1. Overview
    • 7.4.2. Polaris Ultra (Boston Scientific Corporation)
    • 7.4.3. InLay Optima (C.R. Bard)
    • 7.4.4. Other Key Marketed Urinary Tract Stents

8. Clinical Trials to Watch

  • 8.1. Overview
  • 8.2. Enteral Stents
  • 8.3. Pancreatic and Biliary Stents
  • 8.4. Airway Stents
  • 8.5. Urinary Tract Stents

9. Current and Future Players

  • 9.1. Trends in Corporate Strategy
  • 9.2. Company Profiles
    • 9.2.1. Allium Medical
    • 9.2.2. Boston Scientific Corporation
    • 9.2.3. ConMed
    • 9.2.4. Cook Medical
    • 9.2.5. C.R. Bard
    • 9.2.6. Ella-CS
    • 9.2.7. Merit Endotek
    • 9.2.8. M.I. Tech
    • 9.2.9. Micro-Tech (Nanjing)
    • 9.2.10. Medtronic (Covidien)
    • 9.2.11. Novatech
    • 9.2.12. Olympus
    • 9.2.13. Taewoong Medical
    • 9.2.14. Xlumena
    • 9.2.15. Other Companies

10. Market Outlook

  • 10.1. Company Market Share
    • 10.1.1. US
    • 10.1.2. 5EU
    • 10.1.3. South America
    • 10.1.4. Asia-Pacific
  • 10.2. By Market Segment
    • 10.2.1. Global Overview
    • 10.2.2. Enteral Stents
    • 10.2.3. Pancreatic and Biliary Stents
    • 10.2.4. Airway Stents
    • 10.2.5. Urinary Tract Stents
  • 10.3. By Geography
    • 10.3.1. Global Overview
    • 10.3.2. US
    • 10.3.3. EU
    • 10.3.4. South America
    • 10.3.5. Asia-Pacific

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Research Methodology
    • 11.3.1. Overview
    • 11.3.2. Coverage
    • 11.3.3. Secondary Research
  • 11.4. Physicians and Specialists Included in this Study
  • 11.5. Primary Research
    • 11.5.1. Primary Research - Key Opinion Leader Interviews
    • 11.5.2. Primary Research - Physician and Industry Interviews
    • 11.5.3. Expert Panel Validation
  • 11.6. Forecasting Methodology
  • 11.7. About the Authors
    • 11.7.1. Analysts
    • 11.7.2. Global Head of Healthcare
  • 11.8. About MediPoint
  • 11.9. About GlobalData
  • 11.10. Disclaimer

List of Tables

  • Table 1: Ideal Characteristics of a Stent
  • Table 2: Comparison of Silicone and Metal Airway Stents
  • Table 3: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 4: Pancreatic and Biliary Stents Procedure Volumes Forecast for the US, 2011-2021
  • Table 5: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 6: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 7: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 8: Pancreatic and Biliary Stents Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 9: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 10: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 11: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 12: Pancreatic and Biliary Stents Procedure Volumes Forecast for APAC, 2011-2021
  • Table 13: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 14: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 15: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 16: Pancreatic and Biliary Stents Procedure Volumes Forecast for South America, 2011-2021
  • Table 17: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 18: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 19: GPOs in the US and EU
  • Table 20: Regulatory Differences Between the US and EU for Obtaining Approval for Medical Devices
  • Table 21: Medicare National Average Reimbursement Rates for Non-Vascular Stenting Procedures, 2014
  • Table 22: Direct, Indirect, and Intangible Costs of Non-Vascular Stenting
  • Table 23: WallFlex Family Stent Product Portfolio
  • Table 24: WallFlex Stent Family SWOT Analysis
  • Table 25: Evolution Family Stent Product Portfolio
  • Table 26: Evolution Stent Family SWOT Analysis
  • Table 27: Niti-S Family Stent Product Portfolio
  • Table 28: Niti-S Stent Family SWOT Analysis
  • Table 29: Gastrointestinal Stents, Other Key Marketed Products
  • Table 30: WallFlex Biliary RX Stent Product Portfolio
  • Table 31: WallFlex Biliary RX Stent SWOT Analysis
  • Table 32: Cotton-Leung Stent Product Portfolio
  • Table 33: Cotton-Leung Stent SWOT Analysis
  • Table 34: Bonastent Product Portfolio
  • Table 35: Bonastent Stent SWOT Analysis
  • Table 36: Biliary Stents, Other Key Marketed Products
  • Table 37: Dumon Stent Product Portfolio
  • Table 38: Dumon Stent SWOT Analysis
  • Table 39: Aero/Aero DV Stent Product Portfolio
  • Table 40: Aero/Aero DV Stents SWOT Analysis
  • Table 41: Ultraflex Stent Product Portfolio
  • Table 42: Ultraflex Stent SWOT Analysis
  • Table 43: Airway Stents, Other Key Marketed Products
  • Table 44: Polaris Ultra Stent Product Portfolio
  • Table 45: Polaris Ultra Stent SWOT Analysis
  • Table 46: InLay Optima Stent Product Portfolio
  • Table 47: InLay Optima SWOT Analysis
  • Table 48: Urinary Tract Stents, Other Key Marketed Products
  • Table 49: Major Clinical Trials for Enteral Stents
  • Table 50: Major Clinical Trials for Pancreatic and Biliary Stents
  • Table 51: Major Clinical Trial for Airway Stents
  • Table 52: Company Profile - Allium Medical
  • Table 53: Allium Medical's Marketed Non-Vascular Stent Products
  • Table 54: SWOT Analysis - Allium Medical
  • Table 55: Company Profile - Boston Scientific Corporation
  • Table 56: Boston Scientific Corporation's Marketed Non-Vascular Stent Products
  • Table 57: SWOT Analysis - Boston Scientific Corporation
  • Table 58: Company Profile - ConMed
  • Table 59: ConMed, Key Marketed Non-Vascular Stent Products
  • Table 60: SWOT Analysis - ConMed
  • Table 61: Company Profile - Cook Medical
  • Table 62: Cook Medical, Key Marketed Non-Vascular Stent Products
  • Table 63: SWOT Analysis - Cook Medical
  • Table 64: Company Profile - C.R. Bard
  • Table 65: C.R. Bard, Key Marketed Non-Vascular Stent Products
  • Table 66: SWOT Analysis - C.R. Bard
  • Table 67: Company Profile - Ella-CS
  • Table 68: Ella-CS, Key Marketed Non-Vascular Stent Products
  • Table 69: SWOT Analysis - Ella-CS
  • Table 70: Company Profile - Merit Endotek
  • Table 71: Merit Endotek's Key Marketed Non-Vascular Stent Products
  • Table 72: SWOT Analysis - Merit Endotek
  • Table 73: SWOT Analysis - M.I. Tech
  • Table 74: Company Profile - Micro-Tech (Nanjing)
  • Table 75: Micro-Tech (Nanjing), Key Marketed Non- Vascular Stent Products
  • Table 76: SWOT Analysis - Micro-Tech (Nanjing)
  • Table 77: Medtronic (Covidien) Marketed Non-Vascular Stent Products
  • Table 78: SWOT Analysis - Medtronic (Covidien)
  • Table 79: Company Profile - Novatech
  • Table 80: Novatech's Marketed Non-Vascular Stent Products
  • Table 81: SWOT Analysis - Novatech
  • Table 82: Company Profile - Olympus
  • Table 83: Olympus' Key Marketed Non-Vascular Stent Products
  • Table 84: SWOT Analysis - Olympus
  • Table 85: Company Profile - Taewoong Medical
  • Table 86: Taewoong Medical Marketed Products
  • Table 87: SWOT Analysis - Taewoong Medical
  • Table 88: Company Profile - Xlumena
  • Table 89: Xlumena's Key Marketed Non-Vascular Stent Products
  • Table 90: SWOT Analysis - Xlumena
  • Table 91: Other Companies Involved in the Non-Vascular Stents Market, 2014
  • Table 92: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 93: Enteral Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 94: Pancreatic and Biliary Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 95: Airway Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 96: Urinary Tract Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 97: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 98: Non-Vascular Stents Sales ($m) Forecast for the US, 2011-2021
  • Table 99: Non-Vascular Stents Sales ($m) Forecast for the EU, 2011-2021
  • Table 100: Non-Vascular Stents Sales ($m) Forecast for France, 2011-2021
  • Table 101: Non-Vascular Stents Sales ($m) Forecast for Germany, 2011-2021
  • Table 102: Non-Vascular Stents Sales ($m) Forecast for Italy, 2011-2021
  • Table 103: Non-Vascular Stents Sales ($m) Forecast for Spain, 2011-2021
  • Table 104: Non-Vascular Stents Sales ($m) Forecast for the UK, 2011-2021
  • Table 105: Non-Vascular Stents Sales ($m) Forecast for Brazil, 2011-2021
  • Table 106: Non-Vascular Stents Sales ($m) Forecast for APAC, 2011-2021
  • Table 107: Non-Vascular Stents Sales ($m) Forecast for Japan, 2011-2021
  • Table 108: Non-Vascular Stents Sales ($m) Forecast for China, 2011-2021
  • Table 109: Non-Vascular Stents Sales ($m) Forecast for India, 2011-2021
  • Table 110: Non-Vascular Stents - Primary Call Count by Country
  • Table 111: Non-Vascular Stents - Primary Call Count by Type

List of Figures

  • Figure 1: Enteral Stent - Esophageal
  • Figure 2: Biliary Stent
  • Figure 3: Bronchial Stent
  • Figure 4: Prostatic and Urethral Stents
  • Figure 5: Development Timeline for Esophageal Stents
  • Figure 6: Development Timeline for Gastroduodenal Stents
  • Figure 7: Development Timeline for Colorectal Stents
  • Figure 8: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 9: Enteral Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 10: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 11: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 12: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 13: Airway Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 14: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 15: Urinary Tract Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 16: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 17: Enteral Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 18: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 19: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 20: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 21: Airway Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 22: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 23: Urinary Tract Stenting Procedures Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 24: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 25: Enteral Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 26: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 27: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 28: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 29: Airway Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 30: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 31: Urinary Tract Stenting Procedures Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 32: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 33: Enteral Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 34: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 35: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 36: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 37: Airway Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 38: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 39: Urinary Tract Stenting Procedures Forecast for South America By Stent Type, 2013 and 2021
  • Figure 40: US Non-Vascular Stents Market, By Company Share, 2013
  • Figure 41: 5EU Non-Vascular Stents Market, By Company Share, 2013
  • Figure 42: South American Non-Vascular Stents Market, By Company Share, 2013
  • Figure 43: APAC Non-Vascular Stents Market, By Company Share, 2013
  • Figure 44: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 45: Enteral Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 46: Pancreatic and Biliary Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 47: Airway Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 48: Urinary Tract Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 49: Non-Vascular Stents Sales Forecast for the 10MM, 2011-2021
  • Figure 50: Non-Vascular Stents Sales ($m) Forecast for the US, 2011-2021
  • Figure 51: US Non-Vascular Stents Market, By Segment, 2013 and 2021
  • Figure 52: Non-Vascular Stents Sales ($m) Forecast for the EU, 2011-2021
  • Figure 53: Non-Vascular Stents Sales ($m) Forecast for France, 2011-2021
  • Figure 54: French Non-Vascular Stents Market, 2013 and 2021
  • Figure 55: Non-Vascular Stents Sales ($m) Forecast for Germany, 2011-2021
  • Figure 56: German Non-Vascular Stents Market, 2013 and 2021
  • Figure 57: Non-Vascular Stents Sales ($m) Forecast for Italy, 2011-2021
  • Figure 58: Italian Non-Vascular Stents Market, 2013 and 2021
  • Figure 59: Non-Vascular Stents Sales ($m) Forecast for Spain, 2011-2021
  • Figure 60: Spanish Non-Vascular Stents Market, 2013 and 2021
  • Figure 61: Non-Vascular Stents Sales ($m) Forecast for the UK, 2011-2021
  • Figure 62: UK Non-Vascular Stents Market, 2013 and 2021
  • Figure 63: Non-Vascular Stent Sales ($m) Forecast for Brazil, 2011-2021
  • Figure 64: Brazilian Non-Vascular Stents Market, 2013 and 2021
  • Figure 65: Non-Vascular Stents Sales ($m) Forecast for APAC, 2011-2021
  • Figure 66: Nonvascular Stents Sales ($m) Forecast for Japan, 2011-2021
  • Figure 67: Japanese Nonvascular Stents Market, 2013 and 2021
  • Figure 68: Non-Vascular Stents Sales ($m) Forecast for China, 2011-2021
  • Figure 69: Chinese Non-Vascular Stents Market, 2013 and 2021
  • Figure 70: Non-Vascular Stents ($m) Forecast for India, 2011-2021
  • Figure 71: Indian Non-Vascular Stents Market, 2013 and 2021
  • Figure 72: Non-Vascular Stents - Primary Call Count by Country
  • Figure 73: Non-Vascular Stents - Primary Call Count by Type
Back to Top